Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nos Spray
Cleveland, Ohio, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
NOS Therapeutics is a biotechnology company focused on developing novel small molecule inhibitors of nitric oxide synthase (NOS) to treat neurological conditions. The company's primary research targets the overproduction of nitric oxide, which is a key driver of secondary injury in conditions such as traumatic brain injury and stroke. By selectively inhibiting specific NOS isoforms, the company aims to provide neuroprotective benefits and improve clinical outcomes for patients with acute and chronic brain injuries. Their lead programs are currently in the pre-clinical stage, focusing on optimizing drug delivery and efficacy in animal models.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Nos Spray.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nos Spray.